Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with <sup>18</sup>F-FDG PET/CT

<div>A 46-year-old man with sigmoid colon cancer, who showed one metastatic nodule on PET/CT and two metastatic nodules on liver MRI in both hepatic lobes. (a) Axial <sup>18</sup>F-FDG-PET/CT image shows a focal increased uptake in left lateral section of the liver (curved arrow), but there is no definite FDG uptake in right hepatic lobe. (b) Axial image of hepatocyte-phase on liver MRI shows focal signal defects in left lateral section of the liver (curved arrow), and also in the subcapsular portion of right hepatic lobe (arrow), suggesting two metastatic nodules in both hepatic lobes.</div>

BioMed Research International

fig4

Figure 4

Figure 4: Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with <sup>18</sup>F-FDG PET/CT 

Figure 4 | Does the Gadoxetic Acid-Enhanced Liver MRI Impact on the Treatment of Patients with Colorectal Cancer? Comparison Study with 18F-FDG PET/CT 